- Home
- VSTM vs ACIU Comparison
VSTM vs ACIU Comparison
Compare VSTM & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- ACIU
- Stock Information
- Founded
- VSTM 2010
- ACIU 2003
- Country
- VSTM United States
- ACIU Switzerland
- Employees
- VSTM N/A
- ACIU N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- VSTM Health Care
- ACIU Health Care
- Exchange
- VSTM Nasdaq
- ACIU Nasdaq
- Market Cap
- VSTM 263.5M
- ACIU 247.4M
- IPO Year
- VSTM 2012
- ACIU 2016
- Fundamental
- Price
- VSTM $7.20
- ACIU $2.27
- Analyst Decision
- VSTM Strong Buy
- ACIU Strong Buy
- Analyst Count
- VSTM 8
- ACIU 2
- Target Price
- VSTM $12.67
- ACIU $12.00
- AVG Volume (30 Days)
- VSTM 806.1K
- ACIU 211.7K
- Earning Date
- VSTM 03-21-2025
- ACIU 03-17-2025
- Dividend Yield
- VSTM N/A
- ACIU N/A
- EPS Growth
- VSTM N/A
- ACIU N/A
- EPS
- VSTM N/A
- ACIU N/A
- Revenue
- VSTM $10,000,000.00
- ACIU $48,505,404.00
- Revenue This Year
- VSTM N/A
- ACIU $86.78
- Revenue Next Year
- VSTM $117.91
- ACIU $118.22
- P/E Ratio
- VSTM N/A
- ACIU N/A
- Revenue Growth
- VSTM N/A
- ACIU 4097200.00
- 52 Week Low
- VSTM $2.10
- ACIU $2.19
- 52 Week High
- VSTM $13.52
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- VSTM 77.09
- ACIU 37.62
- Support Level
- VSTM $5.40
- ACIU $2.19
- Resistance Level
- VSTM $7.50
- ACIU $2.55
- Average True Range (ATR)
- VSTM 0.43
- ACIU 0.13
- MACD
- VSTM 0.19
- ACIU -0.02
- Stochastic Oscillator
- VSTM 97.38
- ACIU 25.49
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.